City of Hope | Strategic Alliance Partners

August 18, 2021

Alexey V. Danilov, MD, discusses the safety and efficacy achieved with the novel combination comprised of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.

August 09, 2021

City of Hope, a world-renowned cancer research and treatment center, today announced that acclaimed Pacific Shores Medical Group has joined City of Hope.

July 27, 2021

Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.

July 23, 2021

Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.

July 22, 2021

Leanne Burnham, PhD, discusses the need to close the gap in health disparities in prostate cancer.

July 19, 2021

Yung Lyou, MD, PhD, discusses emerging biomarkers in prostate cancer.

July 16, 2021

Yung Lyou, MD, PhD, discusses optimal sequencing with apalutamide in prostate cancer.

July 14, 2021

Leanne Burnham, PhD, discusses health disparities in prostate cancer.

July 14, 2021

Within the hierarchy of clinical trials, phase 3 randomized studies remain the gold standard, though some argue that appropriately designed meta-analysis of multiple studies provides even more definitive and meaningful insight.

July 08, 2021

Dr. Rariy, Ms. Brown, and Ms. Greenman discuss how the COVID-19 pandemic has led to a significant delay in cancer diagnoses, impacted the training of oncologists, and revolutionized telehealth.

June 20, 2021

Tanya Dorff, MD, discusses encouraging data from a study evaluating bright white light in older patients with prostate cancer and updates from the phase ARAMIS trial.

June 19, 2021

City of Hope has entered into a licensing agreement with Imugene Ltd. for the patents covering a combination immunotherapy that enables CD19-directed CAR T-cell therapies to target and eradicate difficult-to-treat solid tumors.

June 16, 2021

Multiple FDA approvals and an increasing number of clinical trials examining molecular target–based therapeutics, including second- or even third-generation drugs against a well-defined target, present an ever-widening array of drugs for routine cancer care based on the discovery of specific molecular targets within the tumor or within the germline.

June 11, 2021

Preeminent oncologist Edward S. Kim, MD, MBA, has been named among the nation’s top cancer leaders by Friends of Cancer Research, a national organization dedicated to advances in science, policy, and regulations that speed lifesaving treatments to patients.

June 08, 2021

Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.

June 05, 2021

Two cases of cytokine release syndrome occurred during the first cycle of step-up dosing; however, both were considered non-severe and were treated without the need of tocilizumab, admission to the ICU or use of vasopressors.

June 02, 2021

Anita Johnson, MD, FACS, discusses existing disparities in cancer, studies that have helped to shed further light on the issue, and ongoing efforts being made to improve outcomes in all patients.

June 01, 2021

Although the COVID-19 vaccine rollout is unprecedented in speed and scope, the process of postapproval surveillance has been shown to be robust and should serve as a source of reassurance to the public regarding the effectiveness of the initial and follow-up review process.

May 21, 2021

Natasha Garg, DO, discusses selecting between antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

May 13, 2021

The challenges of assessing COVID-19 vaccines shows that events in the real world may differ from those of a formal objective scientific analysis, especially in a setting where such evaluations of necessity involve very small numbers.